Technical Analysis for IMMU - Immunomedics, Inc.
|Grade||Last Price||% Change||Price Change|
IMMU closed up 1.46 percent on Thursday, January 17, 2019, on 1.42 times normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
|Weak or Absent||Down||Down||Down|
|See historical IMMU trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 17||50 DMA Resistance||Bearish||-26.26%|
|Jan 17||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||-26.26%|
|Jan 17||Pocket Pivot||Bullish Swing Setup||-26.26%|
|Jan 17||Weak + Overbought||Other||-26.26%|
|Jan 17||Outside Day||Range Expansion||-26.26%|
|Jan 17||Wide Bands||Range Expansion||-26.26%|
|Jan 17||Overbought Stochastic||Strength||-26.26%|
|Jan 16||50 DMA Resistance||Bearish||-25.18%|
|Jan 16||Stochastic Sell Signal||Bearish||-25.18%|
|Jan 16||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||-25.18%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases. Its products include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; Yttrium-90 labeled clivatuzumab tetraxetan, a therapeutic product candidate that completed a Phase Ib clinical trial for the treatment of pancreatic cancer; and Veltuzumab, a humanized anti-CD20 monoclonal antibody for the treatment of non-Hodgkin lymphoma (NHL). The company's products also comprise Milatuzumab, a transmembrane protein that is highly expressed in MM and other B-cell lymphomas and leukemias, and in certain solid tumors; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL; Labetuzumab, a proprietary humanized antibody, which is in Phase II clinical development stage, targets the carcinoembryonic antigen, CEACAM5; and hRS7, an internalizing humanized anti-epithelial glycoprotein-1 antibody. It also manufactures and commercializes LeukoScan, a diagnostic imaging system to determine the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers. The company has strategic partnerships and relationships with Nycomed GmbH and UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more IMMU news...
|52 Week High||27.33|
|52 Week Low||12.86|
|200-Day Moving Average||21.0184|
|50-Day Moving Average||18.2525|
|20-Day Moving Average||16.3175|
|10-Day Moving Average||17.364|
|Average True Range||1.2698|
|Chandelier Exit (Long, 3 ATRs )||15.0906|
|Chandelier Exit (Short, 3 ATRs )||16.6694|
|Upper Bollinger Band||19.1023|
|Lower Bollinger Band||13.5327|
|Percent B (%b)||0.82|
|MACD Signal Line||-0.4194|
|Market Cap||2.01 Billion|
|Num Shares||111 Million|
|Price-to-Earnings (P/E) Ratio||-12.31|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||19.53|
|Resistance 3 (R3)||19.54||19.08||19.29|
|Resistance 2 (R2)||19.08||18.71||19.07||19.21|
|Resistance 1 (R1)||18.58||18.48||18.83||18.57||19.13|
|Support 1 (S1)||17.62||17.75||17.87||17.61||17.05|
|Support 2 (S2)||17.16||17.52||17.15||16.97|
|Support 3 (S3)||16.66||17.16||16.89|
|Support 4 (S4)||16.65|